Immunogen Inc (NASDAQ:IMGN) Quarterly Sentiment Change Report

ImmunoGen, Inc. (NASDAQ:IMGN) Logo

Sentiment for Immunogen Inc (NASDAQ:IMGN)

Immunogen Inc (NASDAQ:IMGN) institutional sentiment increased to 1.29 in 2019 Q1. Its up 0.22, from 1.07 in 2018Q4. The ratio is more positive, as 81 investment professionals increased or opened new holdings, while 63 sold and trimmed holdings in Immunogen Inc. The investment professionals in our partner’s database reported: 113.69 million shares, down from 119.32 million shares in 2018Q4. Also, the number of investment professionals holding Immunogen Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 22 Reduced: 41 Increased: 50 New Position: 31.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $412.18 million. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

The stock decreased 2.83% or $0.08 during the last trading session, reaching $2.75. About 1.10 million shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has declined 76.42% since August 15, 2018 and is downtrending. It has underperformed by 76.42% the S&P500.

Redmile Group Llc holds 1.04% of its portfolio in ImmunoGen, Inc. for 13.06 million shares. Qvt Financial Lp owns 1.38 million shares or 0.87% of their US portfolio. Moreover, Fernwood Investment Management Llc has 0.27% invested in the company for 187,000 shares. The California-based Endurant Capital Management Lp has invested 0.2% in the stock. Birchview Capital Lp, a Vermont-based fund reported 90,000 shares.

ImmunoGen, Inc. (NASDAQ:IMGN) Ratings Coverage

Ratings analysis reveals 50% of ImmunoGen’s analysts are positive. Out of 6 Wall Street analysts rating ImmunoGen, 3 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $2.5 while the high is $12. The stock’s average target of $5.08 is 84.73% above today’s ($2.75) share price. IMGN was included in 13 notes of analysts from March 1, 2019. The firm has “Buy” rating by Guggenheim given on Friday, March 1. The firm has “Neutral” rating by H.C. Wainwright given on Monday, March 4. The rating was downgraded by Piper Jaffray on Friday, March 1 to “Hold”. The rating was downgraded by Jefferies to “Hold” on Friday, March 1. RBC Capital Markets maintained it with “Buy” rating and $6 target in Monday, March 4 report. The rating was maintained by Canaccord Genuity with “Buy” on Friday, March 1.

More notable recent ImmunoGen, Inc. (NASDAQ:IMGN) news were published by: Finance.Yahoo.com which released: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN – Yahoo Finance” on May 15, 2019, also Seekingalpha.com with their article: “ImmunoGen Q4 2018 Earnings Preview – Seeking Alpha” published on February 07, 2019, Nasdaq.com published: “Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for – Nasdaq” on April 26, 2019. More interesting news about ImmunoGen, Inc. (NASDAQ:IMGN) were released by: Seekingalpha.com and their article: “ImmunoGen Q2 2019 Earnings Preview – Seeking Alpha” published on August 01, 2019 as well as Seekingalpha.com‘s news article titled: “ImmunoGen: Bold Move To Position A Comeback – Seeking Alpha” with publication date: July 16, 2019.

ImmunoGen, Inc. (NASDAQ:IMGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.